Exit Interviews to Assess Impact of Infusion Frequency in Hemophilia A

Overview

This study is to generate qualitative data to evaluate the impact of frequency of FVIII infusions on patients' satisfaction with treatment and their quality of life.

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: November 26, 2017

Interventions

  • Biological: BAY94-9027
    • Intravenous infusion of BAY94-9027

Arms, Groups and Cohorts

  • Prophylaxis treatment of BAY94-9027_1
    • 2 infusions per week during the extension study
  • Prophylaxis treatment of BAY94-9027_2
    • infusion every 5 days during the extension study
  • Prophylaxis treatment of BAY94-9027_3
    • every 7 days during the extension study

Clinical Trial Outcome Measures

Primary Measures

  • Qualitative interviews (with patients) to determine patients’ satisfaction
    • Time Frame: up to 4 months
    • To conduct qualitative interviews with patients with Hemophilia A who have participated in the BAY94-9027 extension studies to evaluate patient experiences of and perspectives regarding their current treatment and the extent to which the frequency of FVIII infusions (compared to previous treatments) influences satisfaction
  • Qualitative interviews (with patients) to determine patients’ quality of life
    • Time Frame: up to 4 months
    • To conduct qualitative interviews with patients with Hemophilia A who have participated in the BAY94-9027 extension studies to evaluate patient experiences of and perspectives regarding their current treatment and the extent to which the frequency of FVIII infusions (compared to previous treatments) influences quality of life;
  • Qualitative interviews (with treating physicians) to determine patients’ satisfaction
    • Time Frame: up to 4 months
    • To conduct qualitative interview with clinicians who treat patients with Hemophilia A who have participated in the BAY94-9027 extension studies to evaluate the clinician perspective of patient experiences of and perspectives regarding their current treatment and the extent to which the frequency of FVIII infusions (compared to previous treatments) influences their patients’ satisfaction
  • Qualitative interviews (with treating physicians) to determine patients’ quality of life
    • Time Frame: up to 4 months
    • To conduct qualitative interview with clinicians who treat patients with Hemophilia A who have participated in the BAY94-9027 extension studies to evaluate the clinician perspective of patient experiences of and perspectives regarding their current treatment and the extent to which the frequency of FVIII infusions (compared to previous treatments) influences their patients’ quality of life;

Participating in This Clinical Trial

Inclusion Criteria

  • Patient is enrolled in the BAY94-9027 extension studies or is within 3 months of having completed participation in the BAY94-9027 extension studies; – Patient allocated to Arm 2, Arm 3 or Arm 4 of BAY94-9027 extension studies. – Arm 2 Prophylaxis treatment of BAY94-9027; 2 infusions per week during the extension study – Arm 3 Prophylaxis treatment of BAY94-9027; infusion every 5 days during the extension study – Arm 4 Prophylaxis treatment of BAY94-9027; every 7 days during the extension study – Evidence of a personally signed and dated informed consent document indicating that the patient has been informed of all pertinent aspects of the study; – Patient must be willing and able to participate in a telephone interview lasting up to 30 minutes; – Patient must have sufficient cognitive and linguistic capacities to allow them to actively participate in an interview lasting 30 minutes. Exclusion Criteria:

  • Patient is part of Arm 1: On-demand treatment of BAY94-9027 at individual dose and number of infusions based upon location and severity of bleeds; – Patient is unlikely to comply with the study protocol (e.g. uncooperative attitude) or unlikely to complete the study for any reason in the opinion of the recruiter; – Patient has great difficulty hearing or reading; – Patient has any significant comorbid condition (including uncontrolled psychiatric conditions) that might limit or interfere with their ability to talk about their Hemophilia A and participate in the study; – Patient has severe neurological or cognitive deficits that might affect their ability to participate in an interview.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Bayer
  • Provider of Information About this Clinical Study
    • Sponsor

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.